Off-label Use of Anti-IL-1 Drugs in Rheumatic Diseases

Overview

Journal Int J Immunopathol Pharmacol

Publisher Sage Publications

Specialties Allergy & Immunology
Pathology
Pharmacology

Date 2021 Apr 15

PMID 33855881

Citations 10

Authors

Silvia Stefania

Ripalta Colia

Rotondo Cinzia

Addolorata Corrado

Francesco Paolo Cantatore

Affiliations

Soon will be listed here.

Abstract

Interleukin-1 (IL-1) plays a key role in the pathogenesis of different rheumatic diseases. There are now several agents available on the market capable of blocking IL-1. The proven effectiveness and excellent safety of these drugs makes them a possible therapeutic option in the treatment of IL-1 driven diseases, when previous therapies are contraindicated or ineffective. This article discusses the European wide off-label use of these drugs for the treatment of rheumatic diseases.

Citing Articles

Targeting the NLRP3 inflammasome as a novel therapeutic target for osteoarthritis.

Karmakar V, Chain M, Majie A, Ghosh A, Sengupta P, Dutta S Inflammopharmacology. 2025; 33(2):461-484.

PMID: 39806051 DOI: 10.1007/s10787-024-01629-2.

Development of a novel tool for individual treatment trials in mucopolysaccharidosis.

Wiesinger A, Bigger B, Giugliani R, Lampe C, Scarpa M, Moser T J Inherit Metab Dis. 2024; 48(1):e12816.

PMID: 39572375 PMC: 11670214. DOI: 10.1002/jimd.12816.

Impaired autophagy in myeloid cells aggravates psoriasis-like skin inflammation through the IL-1β/CXCL2/neutrophil axis.

Lee J, Kim M, Kim H, Choi W, Kim H Cell Biosci. 2024; 14(1):57.

PMID: 38704587 PMC: 11069248. DOI: 10.1186/s13578-024-01238-0.

Biomarkers for immune-related adverse events in cancer patients treated with immune checkpoint inhibitors.

Liang Y, Maeda O, Ando Y Jpn J Clin Oncol. 2024; 54(4):365-375.

PMID: 38183211 PMC: 11771318. DOI: 10.1093/jjco/hyad184.

Systematic Review of Roles of Arecoline and Arecoline -Oxide in Oral Cancer and Strategies to Block Carcinogenesis.

Ko A, Tu H, Ko Y Cells. 2023; 12(8).

PMID: 37190117 PMC: 10137008. DOI: 10.3390/cells12081208.

References

Announ N, Palmer G, Guerne P, Gabay C . Anakinra is a possible alternative in the treatment and prevention of acute attacks of pseudogout in end-stage renal failure. Joint Bone Spine. 2009; 76(4):424-6. DOI: 10.1016/j.jbspin.2009.01.001. View

Gran J, Midtvedt O, Haug S, Aukrust P . Treatment of Schnitzler's syndrome with anakinra: report of three cases and review of the literature. Scand J Rheumatol. 2010; 40(1):74-9. DOI: 10.3109/03009742.2010.493894. View

Dein E, Ingolia A, Connolly C, Manno R, Timlin H . Anakinra for Recurrent Fevers in Systemic Lupus Erythematosus. Cureus. 2019; 10(12):e3782. PMC: 6395019. DOI: 10.7759/cureus.3782. View

Ruscitti P, Masedu F, Alvaro S, Airo P, Battafarano N, Cantarini L . Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial. PLoS Med. 2019; 16(9):e1002901. PMC: 6742232. DOI: 10.1371/journal.pmed.1002901. View

Arostegui J, Arnal C, Merino R, Modesto C, Antonia Carballo M, Moreno P . NOD2 gene-associated pediatric granulomatous arthritis: clinical diversity, novel and recurrent mutations, and evidence of clinical improvement with interleukin-1 blockade in a Spanish cohort. Arthritis Rheum. 2007; 56(11):3805-13. DOI: 10.1002/art.22966. View

Lin Z, Hegarty J, Lin T, Ostrov B, Wang Y, Yu W . Failure of anakinra treatment of pyoderma gangrenosum in an IBD patient and relevance to the PSTPIP1 gene. Inflamm Bowel Dis. 2011; 17(6):E41-2. DOI: 10.1002/ibd.21684. View

Schnellbacher C, Ciocca G, Menendez R, Aksentijevich I, Goldbach-Mansky R, Duarte A . Deficiency of interleukin-1 receptor antagonist responsive to anakinra. Pediatr Dermatol. 2012; 30(6):758-60. PMC: 3548019. DOI: 10.1111/j.1525-1470.2012.01725.x. View

Fabiani C, Sota J, Sainz-de-la-Maza M, Pelegrin L, Emmi G, Lopalco G . New Potential Weapons for Refractory Scleritis in the Era of Targeted Therapy. Mediators Inflamm. 2020; 2020:8294560. PMC: 7201583. DOI: 10.1155/2020/8294560. View

Sota J, Vitale A, Insalaco A, Sfriso P, Lopalco G, Emmi G . Safety profile of the interleukin-1 inhibitors anakinra and canakinumab in real-life clinical practice: a nationwide multicenter retrospective observational study. Clin Rheumatol. 2018; 37(8):2233-2240. DOI: 10.1007/s10067-018-4119-x. View

10.

Sun N, Ro T, Jolly P, Sayed C . Non-response to Interleukin-1 Antagonist Canakinumab in Two Patients with Refractory Pyoderma Gangrenosum and Hidradenitis Suppurativa. J Clin Aesthet Dermatol. 2018; 10(9):36-38. PMC: 5749618. View

11.

Jennings L, Molloy O, Quinlan C, Kelly G, OKane M . Treatment of pyoderma gangrenosum, acne, suppurative hidradenitis (PASH) with weight-based anakinra dosing in a Hepatitis B carrier. Int J Dermatol. 2017; 56(6):e128-e129. DOI: 10.1111/ijd.13528. View

12.

Van Wabeke J, Dhondt E, Peene I, Piette Y . Anakinra in resistant gout: a case report. Acta Clin Belg. 2016; 72(4):293-295. DOI: 10.1080/17843286.2016.1239891. View

13.

Nigrovic P, Mannion M, Prince F, Zeft A, Rabinovich C, van Rossum M . Anakinra as first-line disease-modifying therapy in systemic juvenile idiopathic arthritis: report of forty-six patients from an international multicenter series. Arthritis Rheum. 2011; 63(2):545-55. DOI: 10.1002/art.30128. View

14.

Molto A, Ea H, Richette P, Bardin T, Liote F . Efficacy of anakinra for refractory acute calcium pyrophosphate crystal arthritis. Joint Bone Spine. 2012; 79(6):621-3. DOI: 10.1016/j.jbspin.2012.01.010. View

15.

Gattorno M, Pelagatti M, Meini A, Obici L, Barcellona R, Federici S . Persistent efficacy of anakinra in patients with tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum. 2008; 58(5):1516-20. DOI: 10.1002/art.23475. View

16.

de Koning H, Schalkwijk J, van der Meer J, Simon A . Successful canakinumab treatment identifies IL-1β as a pivotal mediator in Schnitzler syndrome. J Allergy Clin Immunol. 2011; 128(6):1352-4. DOI: 10.1016/j.jaci.2011.05.023. View

17.

Garlanda C, Dinarello C, Mantovani A . The interleukin-1 family: back to the future. Immunity. 2013; 39(6):1003-18. PMC: 3933951. DOI: 10.1016/j.immuni.2013.11.010. View

18.

van der Zee H, Prens E . Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report. Dermatology. 2013; 226(2):97-100. DOI: 10.1159/000343221. View

19.

Neel A, Henry B, Barbarot S, Masseau A, Perrin F, Bernier C . Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study. Autoimmun Rev. 2014; 13(10):1035-41. DOI: 10.1016/j.autrev.2014.08.031. View

20.

Zufferey P, Valcov R, Thomas M, Dumusc A, Forien M, So A . Efficacy of anakinra in acute hydroxyapatite calcification-induced joint pain: A retrospective study of 23 cases. Joint Bone Spine. 2018; 86(1):83-88. DOI: 10.1016/j.jbspin.2018.05.008. View